top of page
Pipeline
Phase 3
Phase 2
Target Validation
IND Studies
Phase 1
Phase 2
Phase 3
Target
Colon Cancer
Si44
Target: Xkr8(Oxp)
SMT1
Breast Cancer
Target: iRhom(Dox)
SMT1
SMT
NHL
Target: NTarget
Si44
NSCLC
SMT
Target: mutEGFR
SMT
We built the Trident platform to enable targeting a wide range of cancers – our pipeline is led by POS001, aimed at NSCLC, and followed by other solid tumor indications as well as ALL.
Si44
Colon Cancer
Breast Cancer
44-FREE
NHL
NSCLC
CLL
AML
Multiple
Undisclosed
Phase 3
Phase 2
Phase 1
IND Studies
Target Validation
Target
Target: Xkr8(Oxp)
SMT1
SMT2
SMT
SMT
SMT
SMT
Target: iRhom(Dox)
Target: NTarget
Target: mutEGFR
Target: BTK
Target: BCL2
Target: PD-L1
Target: Combo
SMT
SMT
Colon
Target
PD-L1 x CD3
EGFR x CD3
LGR5 x CD3
TAA x CD3
IND Enabling
Lead
Optimization
Discovery
Phase 1
POS001
Indication: NSCLC
POS002
Indication: GBM
POS003
Indication: Gastric Cancer
POS004
Indication: ALL
POS001
NSCLC
PD-L1 x CD3
EGFR x CD3
GBM
POS002
LGR5 x CD3
Gastric Cancer
POS003
TAA x CD3
ALL
POS004
IND Enabling
Lead
Optimization
Discovery
Target
Indication
Asset
Phase 1
bottom of page